Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Policy / Regulatory

China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year

Fineline Cube Aug 20, 2026
Company Drug

Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light

Fineline Cube Aug 20, 2026
Company Drug

Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China

Fineline Cube Aug 19, 2026
Company Policy / Regulatory

NMPA Approves TINGSN Technology’s Disposable Intracardiac Ultrasound Diagnostic Catheter

Fineline Cube Nov 30, 2023

The National Medical Products Administration (NMPA) has granted market approval to TINGSN Technology, a China-based...

Company Drug

Everest Medicines’ Nefecon NDA for IgAN Accepted for Review in South Korea

Fineline Cube Nov 30, 2023

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that the New Drug Application...

Company Digital

ClouDr Partners with Yangtze River Pharmaceutical to Digitize Chronic Disease Marketing

Fineline Cube Nov 30, 2023

Hangzhou Kang Ming Information Technology Co., Ltd, trading as “ClouDr” (HKG: 9955), has entered into...

Company Policy / Regulatory

CAR T-Cell Therapy Stocks Plunge as FDA Investigates Cancer Reports Linked to Treatments

Fineline Cube Nov 30, 2023

Shares of Chimeric Antigen Receptor (CAR) T cell therapy companies plummeted on November 28, 2023,...

Company Deals

Pfizer Enters Strategic Alliance with Guangdong Government to Boost Biomedicine R&D

Fineline Cube Nov 29, 2023

Pfizer (NYSE: PFE), the US pharmaceutical powerhouse, has signed a strategic memorandum of understanding with...

Company Deals

Bayer Partners with Hurdle to Launch Saliva-Based Age Tests in Global E-Commerce

Fineline Cube Nov 29, 2023

Bayer (ETR: BAYN), the German multinational, has announced a strategic collaboration to globally distribute Hurdle’s...

Company Drug

Merck’s V116 Pneumococcal Vaccine Shows Promising Data Against Pfizer’s Prevnar 20

Fineline Cube Nov 29, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled new data from a late-stage trial...

Policy / Regulatory

China’s Pharma Distribution Market Grows Steadily in 2022, Driven by Retail Sales Surge

Fineline Cube Nov 29, 2023

The Ministry of Commerce (MofCOM) has released its annual statistical review of China’s pharmaceutical distribution...

Company Deals

BMS and Avidity Biosciences Join Forces on $2.2 Billion Cardiology Antibody Oligonucleotide Conjugate Deal

Fineline Cube Nov 29, 2023

Bristol Myers Squibb (BMS, NYSE: BMY) has announced a strategic partnership with Avidity Biosciences (NASDAQ:...

Company Deals

Blue Sail Medical and China National Medical Device Forge Strategic Partnership for Growth

Fineline Cube Nov 29, 2023

Blue Sail Medical Co., Ltd (SHE: 002382), a prominent player in China’s medical device sector,...

Company

Alibaba Health Reports 12.7% Revenue Growth in H1 2023, Driven by Pharmaceutical and Digital Services

Fineline Cube Nov 29, 2023

Alibaba Health Information Technology Ltd (HKG: 0241), based in China, has released its financial results...

Company Drug

JW Therapeutics Secures Priority Review for Carteyva in Relapsed/Refractory Mantle Cell Lymphoma

Fineline Cube Nov 29, 2023

JW Therapeutics (HKG: 2126), based in China, has announced that its CAR-T cell therapy, Carteyva...

Company Drug

Beijing Konruns Pharmaceutical Launches Phase III Study for KC1036 in Advanced Esophageal Cancer

Fineline Cube Nov 29, 2023

Beijing Konruns Pharmaceutical Co., Ltd (SHA: 603590), based in Beijing, has received approval from China’s...

Company Drug

Lee’s Pharmaceutical Secures NMPA Approval for Adasuve, Pioneering Loxapine Inhaler for Agitation

Fineline Cube Nov 29, 2023

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has secured marketing approval from China’s National Medical Products...

Company Medical Device

AK Medical Holdings Receives NMPA Approval for Hip Surgery Navigation System iBot

Fineline Cube Nov 29, 2023

AK Medical Holdings Ltd (HKG: 1789), a Chinese medical technology company, has announced that it...

Company Drug

Gracell Biotechnologies Gets FDA Green Light for FasTCAR-T Therapy in Systemic Lupus Erythematosus

Fineline Cube Nov 29, 2023

Gracell Biotechnologies Inc., a Suzhou-based biotech company (NASDAQ: GRCL), has received approval from the US...

Company Deals

Mabwell Bioscience Enters Thai Market with Licensing Deal with Innobic

Fineline Cube Nov 29, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a Chinese biopharmaceutical company, has announced the signing...

Company Deals

Taihe Weiye Biotechnology Secures RMB 300 Million in Series A+ Financing to Expand Production

Fineline Cube Nov 29, 2023

Chengdu Taihe Weiye Biotechnology Co., Ltd, a Chinese developer of protected amino acids drugs, has...

Company Drug

Dupixent Trial Success Reinforces Potential in Moderate-to-Severe COPD Treatment

Fineline Cube Nov 28, 2023

Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) have announced that a late-stage replicate trial...

Company Drug

AbbVie’s Epcoritamab Earns EMA Review and FDA Breakthrough Designation for Follicular Lymphoma

Fineline Cube Nov 28, 2023

AbbVie’s (NYSE: ABBV) bispecific antibody (BsAb) Tepkinly/Epkinly (epcoritamab) has been accepted for review by the...

Posts pagination

1 … 481 482 483 … 710

Recent updates

  • Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review
  • China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year
  • CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World’s First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030
  • Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light
  • VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Company Policy / Regulatory

China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year

Company

CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World’s First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030

Company Drug

Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.